This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially informed and sometimes misinformed potential consumers. Compounded ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Most people have missed a dose of prescription medication at some point. But if you are taking a glucagon-like peptide-1 drug ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level Mr. Shah Coherent Market Insights Pvt.

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

The findings highlight how the integration of glucagon-like peptide-1 (GLP-1) medications for weight loss is reshaping the ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...